D-TACE-HAIC Combined With Envafolimab and Lenvatinib in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: a Prospective, Single-arm, Phase II Clinical Study
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.
Intrahepatic Cholangiocarcinoma
DRUG: TACE-HAIC, Envafolimab and Lenvatinib
Objective response rate, ORR, The Objective response rate (ORR) was defined as the complete response (CR) rate or the partial response (PR) rate according to RECIST v1.1 criteria., Four weeks after the initiation of medication
Overall survival, OS, The Overall survival (OS) was defined as the time between receiving treatment and observing death or loss of follow-up for any reason., From date of enrollment until the date of death from any cause, assessed up to 60 months|Progression-free survival, PFS, The Progression free survival (PFS) was defined as the time between the start of treatment and the progression of intrahepatic and/or extrahepatic tumors, or the occurrence of death or loss of follow-up for any reason., From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months|Disease control rate, DCR, The Disease control rate (DCR) was defined as the complete response (CR) rate or the partial response (PR) rate or stable disease (SD) rate according to RECIST v1.1 criteria., Four weeks after the initiation of medication|Treatment-related adverse events, TRAEs treatment-related adverse events, The incidence, spectrum and severity of adverse events (AE) and serious adverse events (SAE) were determined according to the NCI-CTCAE V5.0 standard. Dose suspension rate and dose termination rate due to adverse events., From the initiation of medication, with recordings made whenever an adverse reaction occurs, assessed up to 12 months
This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.